4GB.F · Gossamer Bio, Inc

-

Please sign in to comment on 4GB.F

1 Comment

Admin

4 years, 10 months ago

Gossamer Bio, Inc is currently in a long term downtrend where the price is trading 15.3% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Gossamer Bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 18.1% to $-65M since the same quarter in the previous year.

Finally, its free cash flow grew by 20.1% to $-37M since the same quarter in the previous year.

Based on the above factors, Gossamer Bio, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	US38341P1021
Sector	Healthcare
Industry	Biotechnology

Market Cap	488M
PE Ratio	None
Target Price	19.38
Beta	1.95
Dividend Yield	None

ABOUT

Gossamer Bio, Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

4GB.F · Gossamer Bio, Inc

-

Gossamer Bio, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Gossamer Bio, Inc using a moving average strategy